How incretin-based therapies address the spectrum of physiologic disturbance in type 2 diabetes
The Internet Journal of Academic Physician Assistants · 2010
DOI: 10.5580/172c ↗Kurz gefasst
Fachartikel in der Zeitschrift The Internet Journal of Academic Physician Assistants, 2010.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Blood glucose-lowering agents that exert their therapeutic effect through the incretin hormone system are emerging as effective and well-tolerated therapies for type 2 diabetes. Due to their glucose-dependent mode of action these agents are associated with minimal hypoglycemic risk, and do not cause weight gain, thus avoiding limitations associated with many existing treatments that may threaten treatment adherence. Of the two classes of incretin therapies currently available, the GLP-1 receptor agonists have shown the ability to decrease HbA1c to a greater extent than DPP-4 inhibitors, and GLP-1 agonists may also reduce cardiovascular risk through modification of certain known risk factors, including via weight loss. This article explains the rationale behind using incretin-based therapies, summarizes key data from clinical trials of the GLP-1 agonists exenatide and liraglutide, and licensed DPP-4 inhibitors including sitagliptin and saxagliptin, and provides practical guidance on the use of these agents in clinical practice.
Zitieren
APA
(2010). How incretin-based therapies address the spectrum of physiologic disturbance in type 2 diabetes. The Internet Journal of Academic Physician Assistants. https://doi.org/10.5580/172c
Vancouver
How incretin-based therapies address the spectrum of physiologic disturbance in type 2 diabetes. The Internet Journal of Academic Physician Assistants. 2010. doi:10.5580/172c
BibTeX
@article{euvimed2010,
title = {How incretin-based therapies address the spectrum of physiologic disturbance in type 2 diabetes},
journal = {The Internet Journal of Academic Physician Assistants},
year = {2010},
doi = {10.5580/172c}
}
EUVIMED